Recursion RXRX is slated to report first-quarter 2024 results on May 9, after market close. The Zacks Consensus Estimate is pegged at a loss of 43 cents per share. The Zacks Consensus Estimate for ...
Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback